# China NMPA Drug Inspection - Chifeng Yankang Pharmaceutical Co., Ltd. - Angelica dahurica

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/chifeng-yankang-pharmaceutical-co-ltd/4ed977d1-12bb-48bf-96a8-5dedd5f808ed/
Source feed: China

> China NMPA drug inspection for Chifeng Yankang Pharmaceutical Co., Ltd. published December 29, 2017. Drug: Angelica dahurica. The Inner Mongolia Autonomous Region Food and Drug Administration (IMAFDA) announced on December 29, 2017, the results o

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: (Inner Mongolia Food and Drug Administration Announcement No. 80 of 2017) Announcement of the Inner Mongolia Autonomous Region Food and Drug Administration on the Results of Drug Quality Sampling Inspection
- Company Name: Chifeng Yankang Pharmaceutical Co., Ltd.
- Publication Date: 2017-12-29
- Drug Name: Angelica dahurica
- Inspection Finding: The drug "Baizhi" was found to be non-compliant, specifically failing the assay test.
- Action Taken: Relevant food and drug administration departments have promptly taken control measures and lawfully investigated and dealt with the production unit.
- Summary: The Inner Mongolia Autonomous Region Food and Drug Administration (IMAFDA) announced on December 29, 2017, the results of drug quality sampling inspections. These inspections, conducted by various regional drug inspection institutes, identified that seven batches of Chinese medicinal materials and processed Chinese medicinal herbs from several manufacturers failed to meet established quality standards.

Company: https://www.globalkeysolutions.net/companies/chifeng-yankang-pharmaceutical-co-ltd/dc4179c5-73e6-41d0-a077-922b1bb49864/